Boehringer Ingelheim to Cap Out-of-Pocket Cost for Inhalers at $35
Beginning June 1, 2024, eligible patients will pay no more than $35 a month at retail pharmacies for all Boehringer Ingelheim inhalers to treat asthma and chronic obstructive pulmonary disease (COPD). Included are:
- Atrovent HFA (ipratropium bromide HFA) Inhalation Aerosol
- Combivent Respimat® (ipratropium bromide and albuterol) Inhalation Spray
- Spiriva HandiHaler(tiotropium bromide inhalation powder)
- Spiriva Respimat 1.25 mcg (tiotropium bromide) Inhalation Spray
- Spiriva® Respimat 2.5 mcg (tiotropium bromide) Inhalation Spray
- Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray
- Striverdi Respimat (olodaterol) Inhalation Spray
The company said in a press release that it will decrease the list price on some of its inhaler products and will continue providing rebates off the list price of its medicines to insurers and pharmacy benefits managers.
Remote Care Advancement for Heart Failure, COPD and Diabetes Patients
February 24th 2021In this week's episode of Tuning In to the C-Suite podcast, MHE's Briana Contreras spoke with Dr. Rob Kowal, chief medical officer of the Cardiac Rhythm and Heart Failure division at Medtronic. The two discussed how remote monitoring and IoT is changing healthcare and how remote technology is also gaining a wide-spread adoption to monitor patients at home who have chronic conditions like heart failure, chronic obstructive pulmonary disease and diabetes.
Listen
